Indications
Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.
Composition
- Active substance
- roflumilast
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Libertek
- Active substance
- roflumilast
- ATC code
- R03DX08
- Group
- Respiratory system
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- Marketing authorisation holder
- AstraZeneca AB
- Status